RETA (Reata) Bathi resik saben saham (EPS TTM)

Effective management of the drug Skyclarys has provided Reata Pharmaceuticals (RETA) with a stable cash flow. The 12-month YoY change in net income per share visualizes this success, where the value indicates the status of current profitability. The business relies on steady, non-seasonal demand within the neurology sector. High margins from the global sale of proprietary medicines guarantee excellent scalability.
RETA (Reata Pharmaceuticals Inc): rincian analitis lan laporan miturut indikator

This metric measures the net income per share dynamics over twelve months, reflecting the business scaling rate. Growth in this indicator confirms the strategy's effectiveness, while a slowdown signals a risk of asset overvaluation. By analyzing the rolling annual growth of net income per share, an investor determines the value momentum phase. For Reata Pharmaceuticals (RETA), this confirms the financial results stemming from the FDA approval of a unique drug. The successful merger with Biogen solidifies this trend by capitalizing on management's achievements.